0001178913-23-003362.txt : 20231023
0001178913-23-003362.hdr.sgml : 20231023
20231023064318
ACCESSION NUMBER: 0001178913-23-003362
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231018
FILED AS OF DATE: 20231023
DATE AS OF CHANGE: 20231023
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: aMoon Growth Fund Limited Partnership
CENTRAL INDEX KEY: 0001744099
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36138
FILM NUMBER: 231338476
BUSINESS ADDRESS:
STREET 1: 34 YERUSHALAYIM RD.
CITY: RAANANA
STATE: L3
ZIP: 4350110
BUSINESS PHONE: 972(73)3989560
MAIL ADDRESS:
STREET 1: 34 YERUSHALAYIM RD.
CITY: RAANANA
STATE: L3
ZIP: 4350110
FORMER NAME:
FORMER CONFORMED NAME: aMoon 2 Fund Limited Partnership
DATE OF NAME CHANGE: 20180620
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ayala Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001100397
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 841521955
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9 DEER PARK DRIVE
STREET 2: SUITE K-1
CITY: MONMOUTH JUNCTION
STATE: NJ
ZIP: 08852
BUSINESS PHONE: 732 545 1590
MAIL ADDRESS:
STREET 1: 9 DEER PARK DRIVE
STREET 2: SUITE K-1
CITY: MONMOUTH JUNCTION
STATE: NJ
ZIP: 08852
FORMER COMPANY:
FORMER CONFORMED NAME: Advaxis, Inc.
DATE OF NAME CHANGE: 20050105
FORMER COMPANY:
FORMER CONFORMED NAME: GREAT EXPECTATIONS & ASSOCIATES INC
DATE OF NAME CHANGE: 19991203
4
1
ownership.xml
X0508
4
2023-10-18
1
0001100397
Ayala Pharmaceuticals, Inc.
ADXS
0001744099
aMoon Growth Fund Limited Partnership
34 YERUSHALAIM ROAD
BEIT GAMLA, 6TH FLOOR
RA-ANANA
L3
4350110
ISRAEL
0
0
1
0
0
Common Stock
2023-10-18
4
J
0
0
0.00
D
560602
D
This Form 4 is filed to report that the beneficial interest of the Reporting Person in Ayala Pharmaceuticals, Inc., (the "Registrant") was reduced below 10% due to dilution resulting from issuance of approximately 5,913,480 shares of the Common Stock of the Registrant on October 18, 2023 to the former holders of Biosight Ltd. ("Biosight") upon the consummation on October 18, 2023 of the transaction contemplated by the Agreement and Plan of Merger and Reorganization, dated July 26, 2023, by and among the Registrant, Advaxis Israel Ltd. and Biosight. The transaction is more fully described in the Registrant's Form 8-K filed with the Securities and Exchange Commission on October 20, 2023.
The reported shares are held of record by aMoon Growth Fund Limited Partnership ("aMoon Growth Fund"). aMoon Growth Fund G.P. Limited Partnership ("aMoon Growth Fund G.P.") is the sole General Partner of aMoon Growth Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon Growth Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel may have been deemed to have shared voting and investment power with respect to the shares held of record by aMoon Growth Fund. Each of aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Growth Fund except to the extent of its or his pecuniary interest therein, if any.
/s/ Yair Schindel, on behalf of himself and the sole shareholder of aMoon General Partner Ltd., the sole General Partner of aMoon Growth Fund G.P. Limited Partnership, the sole General Partner of aMoon Growth Fund, Limited Partnership
2023-10-23